Search Within

Asia S McCoy

Formats
  1. Meeting Abstract (11)
  2. Journal Article (7)
  3. Review (1)
Groups
  1. Department of Medicine (16)
  2. Genitourinary Oncology Service (16)
  3. Solid Tumor Oncology Division (16)
  4. Biostatistics Service (13)
  5. Epidemiology and Biostatistics (13)
  6. Department of Pathology and Laboratory Medicine (11)

More Groups

People
  1. Jonathan Rosenberg (16)
  2. Dean Bajorin (15)
  3. Gopakumar Iyer (13)
  4. Ashley Regazzi (12)
  5. Irina Ostrovnaya (12)
  6. Hikmat Al-Ahmadie (11)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2022 (1)
  4. 2021 (2)
  5. 2020 (2)
  6. 2019 (2)

More Years

Publications
  1. Journal of Clinical Oncology (12)
  2. Bladder Cancer (2)
  3. Cancer (1)
  4. Cancer Medicine (1)
  5. Clinical Journal of Oncology Nursing (1)
  6. Frontiers in Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (12)
  2. IOS Press (2)
  3. Oncology Nursing Society (ONS) (2)
  4. Wiley Blackwell (2)
  5. Frontiers Media S.A. (1)

Results (19)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)
    Meeting Abstract

    Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO)
    Meeting Abstract

    Gupta, A.; Whiting, K.; Keegan, N. M.; Schmalz, J.; Al-Ahmadie, H. A.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Iyer, G.; Rosenberg, J. E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer
    Review

    Brower, B.; McCoy, A.; Ahmad, H.; Eitman, C.; Bowman, I. A.; Rembisz, J.; Milowsky, M. I.
    Frontiers in Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: A multicenter, single-arm, phase II trial
    Journal Article

    Funt, S. A.; Lattanzi, M.; Whiting, K.; Al-Ahmadie, H.; Quinlan, C.; Teo, M. Y.; Lee, C. H.; Aggen, D.; Zimmerman, D.; McHugh, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial
    Meeting Abstract

    Funt, S. A.; Lattanzi, M.; Whiting, K.; Al-Ahmadie, H. A.; Quinlan, C.; Teo, M. Y.; Kamradt, J.; Khalil, M. F.; Ostrovnaya, I.; McCoy, A. S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract
    Journal Article

    Sarfaty, M.; Whiting, K.; Teo, M. Y.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; Jungbluth, A. A.; more...
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma
    Journal Article

    McPherson, V.; Reardon, B.; Bhayankara, A.; Scott, S. N.; Boyd, M. E.; Whiting, K.; Garcia-Grossman, I. R.; Regazzi, A. M.; McCoy, A. S.; Kim, P. H.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract
    Meeting Abstract

    Sarfaty, M.; Ostrovnaya, I.; Teo, M. Y.; Iyer, G.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Keegan, N. M.; Funt, S. A.; Kania, B. E.; Iyer, G.; Clement, J. M.; McCoy, A. S.; Hettich, G.; Ziv, E.; Maher, C. A.; Nair, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save